The Utility of Automated ASPECTS in Acute Ischemic Stroke for Intravenous Recombinant Tissue Plasminogen Activator (IV-rtPA) Therapy.

Content Provider	Europe PMC
Author	Shibata, Soichiro Sakurai, Kenzo Tachikawa, Keiji Ko, Riyoko Hino, Sakae Fukano, Takayuki Isahaya, Kenji Haraguchi, Takafumi Yamauchi, Junji Tanabe, Kenichiro Nagasaka, Misako Hagiwara, Yuta Shimizu, Takahiro Akiyama, Hisanao Kobayashi, Yasuyuki Hasegawa, Yasuhiro Yamano, Yoshihisa
Editor	Chavda, Vishal K. Chaurasia, Bipin Montemurro, Nicola
Copyright Year	2022
Abstract	Purpose: This study aimed to investigate the accuracy and clinical significance of an artificial intelligence (AI)-based automated Alberta Stroke Program Early Computed Tomography (ASPECT) scoring software of head CT for the indication of intravenous recombinant tissue plasminogen activator (rt-PA) therapy. Methods: This study included two populations of acute ischemic stroke: one comprised patients who had undergone head CT within 48 h of presentation (Population #1, n = 448), while the other included patients within 4.5 h from onset (Population #2, n = 132). The primary endpoint was the concordance rate of ASPECTS of the neurologists and AI software against the benchmark score. The secondary endpoints were to validate the accuracy of the neurologist and AI software in assessing the ability to rule out extensive infarction (ASPECTS of 0–5) in population #2. Results: The reading accuracy of AI software was comparable to that of the board-certified vascular neurologists. The detection rate of cardiogenic cerebral embolism was better than that of atherothrombotic cerebral infarction. By excluding extensive infarction, AI-software showed a higher specificity and equivalent sensitivity compared to those of experts. Conclusions: The AI software for ASPECTS showed convincing agreement with expert evaluation and would be supportive in determining the indications of intravenous rt-PA therapy.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC9680239&blobtype=pdf
ISSN	20358385
Journal	Neurology International [Neurol Int]
Volume Number	14
DOI	10.3390/neurolint14040077
PubMed Central reference number	PMC9680239
Issue Number	4
PubMed reference number	36412699
e-ISSN	20358377
Language	English
Publisher	MDPI
Publisher Date	2022-11-21
Access Restriction	Open
Rights License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). © 2022 by the authors.
Subject Keyword	artificial intelligence recombinant tissue plasminogen activator therapy ASPECTS acute cerebral infarction
Content Type	Text
Resource Type	Article
Subject	Neurology (clinical)